Clinical Efficacy Study of PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Advanced Endometrial Cancer

This study tests whether adding a PD-1 immune checkpoint inhibitor (immunotherapy) to standard chemotherapy before surgery improves outcomes for women with advanced endometrial cancer (uterine cancer) that is not yet operable due to its stage. **You may be eligible if...** - You are aged 18–75 with confirmed endometrial cancer at stage III (inoperable) or stage IV - Your cancer has not yet been treated - Your general health score is 0 or 1 (able to carry out normal activities) - Your blood counts and organ function are within acceptable ranges **You may NOT be eligible if...** - You have an active autoimmune disease (with limited exceptions) - You have previously received immunotherapy or immune checkpoint inhibitors - You have active hepatitis B, hepatitis C, HIV, or tuberculosis - You have had a prior bone marrow or organ transplant - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.